相关实验视频
Updated: Jul 23, 2026

06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
35.1K
通过生物信息学和体外实验来确定与前列腺癌骨转移相关的基因和潜在的治疗点
Haiyang Jiang1,2, Mingcheng Liu3, Yingfei Deng4
1Department of Urology I, The Third Affiliated Hospital of Kunming Medical University (Peking University Cancer Hospital Yunnan, Yunnan Cancer Hospital, Cancer Center of Yunnan Province), Kunming, Yunnan, China.
Journal of cellular and molecular medicine
|August 4, 2024
概括
研究人员确定了七个关键基因驱动前列腺癌骨转移. 一个高度表达的基因APOC1显著影响癌症的进展,并可能作为治疗点.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 前列腺癌 (PCa) 骨转移背后的机制尚未完全理解.
- 确定关键的遗传驱动因素对于开发向疗法至关重要.
研究的目的:
- 为了确定与前列腺癌骨转移相关的枢纽基因.
- 探索PCa骨转移的潜在治疗点和预后标志物.
主要方法:
- 利用机器学习,基因本体学 (GO),KEGG,基因组丰富分析 (GSEA),单细胞分析和接收器操作特征 (ROC) 方法.
- 分析了TCGA和GEO数据库中的数据,用患者样本验证了发现,并进行了体外实验.
主要成果:
- 鉴定了七个枢纽基因 (APOC1,CFH,NUSAP1,LGALS1,NR4A2,ADRB2,ZNF331) 具有高的诊断准确性 (AUC为0.727-0.926).
- 在骨转移组织中发现APOC1,CFH,NUSAP1和LGALS1的上调.
- 发现APOC1沉默在体外抑制PCa细胞的增殖,克隆性和迁移,并与临床特征有关.
结论:
- 七个枢纽基因,特别是APOC1,通过线粒体代谢重编程参与前列腺癌骨转移.
- APOC1显示作为治疗点和前列腺癌与骨转移的预后标志物具有前列腺癌的潜力.
相关概念视频
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

